The hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan provides a novel option for patients with von Hippel–Lindau disease-associated RCC and has expanded into broader RCC indications [142]. Here, EPAS1 is linked to renal cell carcinoma.